Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

<< Previous

Bullboard Posts

Next >>

Post by Duster340on Nov 23, 2022 12:31pm

243 Views

Post# 35122359

More details needed

Initiate Phase II bunionectomy trial – calendar H1 2023

this is the elephant in the room, until we get some information the stock is in a holding pattern.
>how long will the trial be? > when will P2 begin? we know it will be anytime between jan/1 to jun/30, if they wait until june that will be another dissapointment and will raise more questions like are they still tweaking the new formula, do they have the science figured out. (more delays? in this case the stock will sell-off.)

<< Previous

Bullboard Posts

Next >>

Grand Portage Resources pioneers new gold exploration in Alaska